Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Contact information



Primary contact

Ms Maria Martinez


Contact details

Hammersmith Hospital
Du Cane Road
W12 0HS
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number

13614, PKB116611

Study information

Scientific title

AKTRES study: A Biologic Study of the early effects and determinants of AKT inhibition using GSK2110183 alongside chemotherapy in patients with platinum RESistant adenocarcinoma of the ovary



Study hypothesis

Activation of the AKT signalling pathway in ovarian cancer cells causes chemotherapy resistance. An AKT inhibitor, given alongside chemotherapy, could potentially reverse this resistance and enable chemotherapy to be effective once again. This study is designed for women whose ovarian cancer has relapsed within 6 months of receiving carboplatin or cisplatin-containing chemotherapy and who are receiving an AKT inhibitor given alongside 3 weekly carboplatin and paclitaxel in the PKB116611 trial. Participants in the AKTRES study undergo a maximum of two biopsies from their tumour and some additional blood tests. The aims of the study are to better understand the how chemotherapy-resistant cancer cells are affected by AKT inhibitors.

Ethics approval

London Hampstead, 07/11/2012, ref. 12/LO/1174

Study design

Non-randomised; Interventional; Design type: Process of Care, Treatment

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Topic: National Cancer Research Network; Subtopic: Gynaecological Cancer; Disease: Ovary/Fallopian tube


Blood sampling, [3x 10mls whole blood collected in greentopped (heparinised) tube] will be collected at baseline (within 14 days prior to first dose), on day 1 (immediately preceding chemotherapy), day 8 and day 15 of cycle 1 only. Blood sampling will subsequently be performed at day 1 only of subsequent chemotherapy treatment cycles and thereafter 3 weekly for those on maintenance GSK2110183 alone. A final 3 x 10mls blood sample will be taken at end of study visit.
Coagulation profile, will be collected immediately prior to the first biopsy during the screening period and postcycle 1 biopsy on day 22. This is in addition to the screening coagulation blood test required for PKB116611 study.
Collection of ascites: If patients are undergoing ascitic or pleural drainage for symptom relief prior to, or during, this study a sample of ascites (or pleural effusion) can be taken and stored. The preferred times for collection are during screening, day 22 and at study completion, but additional/alternative collections can be obtained at the investigators’ discretion.
Tumour Biopsy: A tumour biopsy performed under image guidance within 14 days prior to first dose. Three tumour cores will be taken, two will be fresh frozen and one will be formalin fixed. Following one complete treatment cycle (day 22), =3 days prior to starting cycle 2 day 1, a second tumour biopsy will be performed under image guidance. Again, three tumour cores will be taken, two will be fresh frozen and one will be formalin fixed. Patients can decline the second biopsy if they wish to.

Intervention type



Not Applicable

Drug names


Primary outcome measure

Overall Response, CA125 response and Progression free survival measured by ELISA detected decrease in phosphorylated PRAS40 (as ratio of total PRAS40) and increase in pAKT S473

Secondary outcome measures

Not provided at time of registration

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Female at least 18 years of age at the time of signing the informed consent form
2. Capable of giving written informed consent
3. Having measurable tumour tissue and Platinum-resistant ovarian cancer as defined as radiological evidence of disease progression within 6 months of completion of platinum-containing chemotherapy
4. Tumour tissue measuring >2cm long axis amenable to direct biopsy or biopsy via image-guidance

Participant type


Age group




Target number of participants

Planned Sample Size: 24; UK Sample Size: 12

Participant exclusion criteria

Concurrent medication with warfarin or low molecular weight heparin (heparin use is acceptable if it has been discontinued for 2 days preceding biopsy)

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Hammersmith Hospital
W12 0HS
United Kingdom

Sponsor information


Imperial College of Science, Technology and Medicine (UK)

Sponsor details

Department of Cancer Medicine
Charing Cross Hospital
Fulham Palace Road
W6 8RF
United Kingdom

Sponsor type




Funder type


Funder name

Ovarian Cancer Action (UK)

Alternative name(s)

Funding Body Type

private sector organisation

Funding Body Subtype

Other non-profit organizations


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

08/02/2017: No publications found in PubMed, verifying study status with principal investigator.